The following is a summary of “Influence of Sex, Body Mass Index, and Age on Cellular and Humoral Immune Responses Against Measles After a Third Dose of Measles-Mumps-Rubella Vaccine,” published in the 1 January 2023 issue of Infectious Diseases by Quach, et al.

In the event of a mumps outbreak, a third dose of the measles-mumps-rubella (MMR3) vaccination was advised. However, the immunological response and the necessity of MMR3’s widespread usage still need to be discovered. Therefore, for a study, 232 healthy individuals’ immunological responses to MMR3 were examined by researchers for measles-specificity.

At day 0 and day 28 following MMR3, serum and peripheral blood mononuclear cells (PBMCs) were obtained. A microneutralization technique and an enzyme-linked immunosorbent assay were used to measure the amount of measles-specific binding and neutralizing antibodies in sera. A multiplex test was used to measure the release of cytokines and chemokines after measles virus inactivation stimulated PBMCs. Subjects’ demographic information was investigated for any possible links to immunological results.

At day 0 and day 28, respectively, 95.69% and 100% of the trial subjects were seropositive. Antibody avidity rose noticeably over the course of 28 days, rising from 38.08% at day 0 to 42.8% (P =.00026). By a large margin, neutralizing antibodies increased from 928.7 mIU/mL at day 0 to 1,289.64 mIU/mL on day 28 (P =.0001). The cytokine/chemokine responses, meanwhile, were basically unaltered. Inflammatory cytokines/chemokines were substantially linked with body mass index.

In order to further the understanding of immune responses to MMR3 and support the administration of MMR3 to seronegative or high-risk people, measles-specific humoral immune responses—but not cellular immune responses—were improved following MMR3 receipt.

Reference: academic.oup.com/jid/article-abstract/227/1/141/6673362?redirectedFrom=fulltext